{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:29:36Z","timestamp":1791772176656,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC2108"],"award-info":[{"award-number":["2024NSFSC2108"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304420"],"award-info":[{"award-number":["82304420"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31800690"],"award-info":[{"award-number":["31800690"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejpb.2025.114972","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T16:20:47Z","timestamp":1766420447000},"page":"114972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Sulfasalazine\u2013quercetin co-amorphous systems: Sustained release behaviors and enhanced pharmacokinetics"],"prefix":"10.1016","volume":"220","author":[{"given":"Jia","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangwen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-0156","authenticated-orcid":false,"given":"Qian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1706-396X","authenticated-orcid":false,"given":"Ningbo","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8330-0660","authenticated-orcid":false,"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6936-9197","authenticated-orcid":false,"given":"Hailu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8234-0292","authenticated-orcid":false,"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114972_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.powtec.2024.120458","article-title":"Upscaling co-amorphous formulation of naringin-quinacrine dihydrochloride translating from laboratory to pilot scale using spray drying for improved physicochemical and mechanical properties","volume":"451","author":"Katukam","year":"2025","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2025.114972_b0010","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.2042-7158.2010.01030.x","article-title":"Pharmaceutical applications of cyclodextrins: basic science and product development","volume":"62","author":"Loftsson","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114972_b0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2015.12.009","article-title":"Recent advances in co-amorphous drug formulations","volume":"100","author":"Dengale","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2025.114972_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.apsb.2018.08.002","article-title":"Advances in coamorphous drug delivery systems","volume":"9","author":"Shi","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2025.114972_b0025","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/mp500303a","article-title":"Computational predictions of glass-forming ability and crystallization tendency of drug molecules","volume":"11","author":"Alhalaweh","year":"2014","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114972_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114667","article-title":"Raloxifene HCl \u2013 Naringin co-amorphous system: Preparation, characterization and pharmacokinetic studies","volume":"209","author":"Kola Srinivas","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125056","article-title":"Multi-method coamorphous systems of lumefantrine with alpha ketoglutaric acid: Comprehensive characterization, biological evaluation and stability analysis","volume":"669","author":"Khemchandani","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107033","article-title":"Exploration of enalapril-lacidipine co-amorphous system with superior dissolution, in vivo absorption and physical stability via incorporated into mesoporous silica","volume":"207","author":"Guo","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114972_b0045","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1021\/acs.molpharmaceut.4c00303","article-title":"Computational-based polyphenol therapy for nonsmall cell lung cancer: Naringin coamorphous systems for solubility and bioavailability enhancement","volume":"21","author":"Yarlagadda","year":"2024","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114972_b0050","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3390\/pharmaceutics13101725","article-title":"Deaggregation and crystallization inhibition by small amount of polymer addition for a co-amorphous curcumin-magnolol system","volume":"13","author":"Han","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114972_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120389","article-title":"Sinomenine-phenolic acid coamorphous drug systems: solubilization, sustained release, and improved physical stability","volume":"598","author":"Chen","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120894","article-title":"Co-amorphous systems of sinomenine with nonsteroidal anti-inflammatory drugs: A strategy for solubility improvement, sustained release, and drug combination therapy against rheumatoid arthritis","volume":"606","author":"Chen","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0065","article-title":"Characterization of co-amorphous sinomenine-tranilast systems with strong intermolecular interactions and sustained release profiles","volume":"71","author":"Chen","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2025.114972_b0070","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1021\/acs.molpharmaceut.2c00785","article-title":"Co-amorphous systems of sinomenine with platensimycin or sulfasalazine: Physical stability and excipient-adjusted release behavior","volume":"19","author":"Chen","year":"2022","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114972_b0075","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejpb.2022.09.002","article-title":"Platensimycin-berberine chloride co-amorphous drug system: Sustained release and prolonged half-life","volume":"179","author":"Wang","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/pharmaceutics14030603","article-title":"Sustained release of co-amorphous matrine-type alkaloids and resveratrol with anti-COVID-19 potential","volume":"14","author":"Hu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114972_b0085","first-page":"1837","article-title":"Sulfasalazine in ionic liquid form with improved solubility and exposure","volume":"6","author":"Shadid","year":"2015","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114972_b0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-198510040-00001","article-title":"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid","volume":"10","author":"Klotz","year":"1985","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2025.114972_b0095","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1039\/D3NR04733D","article-title":"A polymeric iron oxide nanocomplex loaded with sulfasalazine: An approach for inducing ferritinophagy-assisted ferroptosis for anti-cancer therapy","volume":"16","author":"Lim","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2025.114972_b0100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.7150\/ijms.30380","article-title":"Anti-cancer effects of sulfasalazine and vitamin e succinate in MDA-MB 231 triple-negative breast cancer cells","volume":"16","author":"Wei","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.ejpb.2025.114972_b0105","doi-asserted-by":"crossref","first-page":"G371","DOI":"10.1152\/ajpgi.00102.2009","article-title":"Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting","volume":"297","author":"Dahan","year":"2009","journal-title":"Am. J. Physiol.-Gastroint. Liver Physiol."},{"key":"10.1016\/j.ejpb.2025.114972_b0110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10965-019-1788-3","article-title":"Fabrication of HPMC and Hibiscus esculentus (okra) gum based microspheres loaded with sulfasalazine and dexamethasone","volume":"26","author":"Mehmood","year":"2019","journal-title":"J. Polym. Res."},{"key":"10.1016\/j.ejpb.2025.114972_b0115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.carbpol.2016.09.038","article-title":"Dimethyl-beta-cyclodextrin\/salazosulfapyridine inclusion complex-loaded chitosan nanoparticles for sustained release","volume":"156","author":"Tang","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2025.114972_b0120","doi-asserted-by":"crossref","unstructured":"M.A.B.d. Costa, A.L.V. Villa, R.d.C.d.S.A. Barros, E. Ricci-J\u00fanior, E.P.d. Santos, Development, characterization and evaluation of the dissolution profile of sulfasalazine suspensions, Braz. J. Pharm. Sci., 51 (2015) 449\u2013459.","DOI":"10.1590\/S1984-82502015000200022"},{"key":"10.1016\/j.ejpb.2025.114972_b0125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2515\/therapie\/2013064","article-title":"Effets ind\u00e9sirables de la sulfasalazine : discussion de leur m\u00e9canisme et du r\u00f4le de la composante sulfamid\u00e9e","volume":"68","author":"Atheymen","year":"2013","journal-title":"Therapies"},{"key":"10.1016\/j.ejpb.2025.114972_b0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jiec.2021.10.028","article-title":"Improving pharmacologically relevant properties of sulfasalazine loaded in \u03b3-cyclodextrin-based metal organic framework","volume":"106","author":"Agafonov","year":"2022","journal-title":"J. Ind. Eng. Chem."},{"key":"10.1016\/j.ejpb.2025.114972_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.129874","article-title":"Non-ionic surfactant vesicles as novel delivery systems for sulfasalazine: Evaluation of the physicochemical and cytotoxic properties","volume":"1230","author":"Aghaei","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejpb.2025.114972_b0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.colsurfa.2018.03.048","article-title":"Enhanced solubility and self-assembly of amphiphilic sulfasalazine-PEG-OMe (S-PEG) conjugate into core-shell nanostructures useful for colonic drug delivery","volume":"547","author":"Priyam","year":"2018","journal-title":"Colloid Surf. A-Physicochem. Eng. Asp."},{"key":"10.1016\/j.ejpb.2025.114972_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2019.111076","article-title":"Impact of Pluronics of different structure on pharmacologically relevant properties of sulfasalazine and methotrexate","volume":"289","author":"Volkova","year":"2019","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ejpb.2025.114972_b0150","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/00319104.2022.2076234","article-title":"The effect of cosolvents and surfactants on the solubility of sulfasalazine","volume":"60","author":"Ardi","year":"2022","journal-title":"Phys. Chem. Liq."},{"key":"10.1016\/j.ejpb.2025.114972_b0155","article-title":"Controlled release of sulfasalazine loaded amidated pectin microparticles through Eudragit S 100 coated capsule for management of inflammatory bowel disease","volume":"55","author":"Deshmukh","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2025.114972_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114475","article-title":"Co-amorphous systems of sulfasalazine with matrine-type alkaloids: Enhanced solubility behaviors and synergistic therapeutic potential","volume":"203","author":"Chen","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0165","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijpharm.2009.11.021","article-title":"MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting","volume":"386","author":"Dahan","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0170","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.3390\/nu12082306","article-title":"Inhibitory effects of quercetin and its main methyl, sulfate, and glucuronic acid conjugates on cytochrome P450 enzymes, and on OATP, BCRP and MRP2 transporters","volume":"12","author":"Mohos","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.ejpb.2025.114972_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106654","article-title":"Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis","volume":"192","author":"Alhajj","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114972_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121657","article-title":"Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system","volume":"618","author":"Alhajj","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/pharmaceutics13020171","article-title":"Co-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugs","volume":"13","author":"Ruponen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114972_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118653","article-title":"The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer","volume":"570","author":"Sormunen","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0195","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejpb.2014.12.025","article-title":"Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of Ritonavir with Quercetin","volume":"89","author":"Dengale","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0200","first-page":"733","article-title":"Quercetin: Potentials in the prevention and therapy of disease","volume":"11","author":"Bischoff","year":"2008","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.ejpb.2025.114972_b0205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s11658-024-00531-7","article-title":"Mechanistic role of quercetin as inhibitor for adenosine deaminase enzyme in rheumatoid arthritis: systematic review","volume":"29","author":"Atta","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ejpb.2025.114972_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120935","article-title":"Silk fibroin nanoparticles enhance quercetin immunomodulatory properties in DSS-induced mouse colitis","volume":"606","author":"Diez-Echave","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0215","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1021\/acs.cgd.9b00294","article-title":"Cocrystals of natural products: improving the dissolution performance of flavonoids using betaine","volume":"19","author":"Zhang","year":"2019","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2025.114972_b0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejpb.2012.02.004","article-title":"Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions","volume":"81","author":"L\u00f6bmann","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0225","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","article-title":"DDSolver: An add-in program for modeling and comparison of drug dissolution profiles","volume":"12","author":"Zhang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2025.114972_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2025.127225","article-title":"Enhancing solubility, bioavailability and anti-cancer efficacy of aprepitant through a naringin-based co-amorphous system","volume":"425","author":"Pardhi","year":"2025","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ejpb.2025.114972_b0235","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1211\/jpp.61.12.0001","article-title":"Review: physical chemistry of solid dispersions","volume":"61","author":"Janssens","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114972_b0240","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1021\/mp900304p","article-title":"Predicting the formation and stability of amorphous small molecule binary mixtures from computationally determined flory-huggins interaction parameter and phase diagram","volume":"7","author":"Pajula","year":"2010","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114972_b0245","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1039\/C9RA07149K","article-title":"A novel drug\u2013drug coamorphous system without molecular interactions: Improve the physicochemical properties of tadalafil and repaglinide","volume":"10","author":"Su","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2025.114972_b0250","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jconrel.2023.01.019","article-title":"Mechanistic insights into the crystallization of coamorphous drug systems","volume":"354","author":"Heng","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2025.114972_b0255","doi-asserted-by":"crossref","first-page":"o226","DOI":"10.1107\/S0108270104003026","article-title":"The imide tautomer of sulfasalazine","volume":"60","author":"Blake","year":"2004","journal-title":"Acta Crystallogr. Sect. C-Struct. Chem."},{"key":"10.1016\/j.ejpb.2025.114972_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103883","article-title":"Drug\u2013drug co-amorphous systems: An emerging formulation strategy for poorly water-soluble drugs","volume":"29","author":"Wang","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2025.114972_b0265","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tca.2012.04.015","article-title":"Physicochemical properties and thermal stability of quercetin hydrates in the solid state","volume":"539","author":"Borghetti","year":"2012","journal-title":"Thermochim Acta"},{"key":"10.1016\/j.ejpb.2025.114972_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125139","article-title":"Piperine as a molecular bridge mediates a ternary coamorphous system of polyphenols with enhanced pharmaceutical properties","volume":"670","author":"Ke","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114972_b0275","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1107\/S0108270100020771","article-title":"Triclinic polymorph of sulfasalazine","volume":"57","author":"Filip","year":"2001","journal-title":"Acta Crystallogr. Sect. C-Struct. Chem."},{"key":"10.1016\/j.ejpb.2025.114972_b0280","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jcrysgro.2016.12.017","article-title":"Modification of solid-state property of sulfasalazine by using the supercritical antisolvent process","volume":"460","author":"Wu","year":"2017","journal-title":"J. Cryst. Growth"},{"key":"10.1016\/j.ejpb.2025.114972_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124913","article-title":"Evaluation of aspartame as a co-former in the preparation of co-amorphous formulations of dipyridamole using spray drying","volume":"667","author":"Kamruzzaman","year":"2024","journal-title":"Int. J. Pharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125003509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125003509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:01:03Z","timestamp":1768960863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125003509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":57,"alternative-id":["S0939641125003509"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114972","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sulfasalazine\u2013quercetin co-amorphous systems: Sustained release behaviors and enhanced pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114972"}}